Simultaneous inhibition of Chk1 and Bcl-xL induces apoptosis in vitro and represses tumour growth in an in vivo xenograft model

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA A Cancer J Clin. 2019;69(1):7–34.
   PubMed Web of Science ®Google Scholar
• Sharma C, Eltawil KM, Renfrew PD, et al. Advances in diagnosis, treatment and palliation of pancreatic carcinoma: 1990–2010. World J Gastroenterol. 2011;17(7):867–897.
   PubMed Web of Science ®Google Scholar
• Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817–1825.
   PubMed Web of Science ®Google Scholar
• Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691–1703.
   PubMed Web of Science ®Google Scholar
• Shirasaka T, Shimamato Y, Ohshimo H, et al. Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs. 1996;7(5):548–557.
   PubMed Web of Science ®Google Scholar
• Yoshizawa J, Takizawa A, Takeuchi O, et al. Experimental study of combination therapy with S-1 against pancreatic cancer. Cancer Chemother Pharmacol. 2009;64(6):1211–1219.
   PubMed Web of Science ®Google Scholar
• Morimoto Y, Takeuchi O, Takizawa A, et al. Effect of a combination of S-1 and gemcitabine on cell cycle regulation in pancreatic cancer cell lines. Anticancer Drugs. 2012;23(5):505–514.
   PubMed Web of Science ®Google Scholar
• Morimoto Y, Takada K, Takeuchi O, et al. Prexasertib increases the sensitivity of pancreatic cancer cells to gemcitabine and S‑1. Oncol Rep. 2020;43(2):689–699.
   PubMed Web of Science ®Google Scholar
• Morimoto Y, Takada K, Takeuchi O, et al. Bcl-2/Bcl-xL inhibitor navitoclax increases the antitumor effect of Chk1 inhibitor prexasertib by inducing apoptosis in pancreatic cancer cells via inhibition of Bcl-xL but not Bcl-2. Mol Cell Biochem. 2020;472(1–2):187–198.
   PubMed Web of Science ®Google Scholar
• Adams JM, Cory S. The bcl-2 apoptotic switch in cancer development and therapy. Oncogene. 2007;26(9):1324–1337.
   PubMed Web of Science ®Google Scholar
• Doerflinger M, Glab JA, Puthalakath H. BH3-only proteins: a 20-year stock-take. FEBS J. 2015;282(6):1006–1016.
   PubMed Web of Science ®Google Scholar
• Seymour JF, Kipps TJ, Eichhorst B, et al. Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2018;378(12):1107–1120.
   PubMed Web of Science ®Google Scholar
• Kipps TJ, Eradat H, Grosicki S, et al. A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia. Leuk Lymphoma. 2015;56(10):2826–2833.
   PubMed Web of Science ®Google Scholar
• Mittal P, Singh S, Sinha R, et al. Myeloid cell leukemia 1 (MCL-1): structural characteristics and application in cancer therapy. Int J Biol Macromol. 2021;187:999–1018.
   PubMed Web of Science ®Google Scholar
• Kastan MB, Bartek J. Cell-cycle checkpoints and cancer. Nature. 2004;432(7015):316–323.
   PubMed Web of Science ®Google Scholar
• Qiu Z, Oleinick NL, Zhang J. ATR/CHK1 inhibitors and cancer therapy. Radiother Oncol. 2018;126(3):450–464.
   PubMed Web of Science ®Google Scholar
• DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383(7):617–629.
   PubMed Web of Science ®Google Scholar
• Wei AH, Roberts AW, Spencer A, et al. Targeting MCL-1 in hematologic malignancies: rationale and progress. Blood Rev. 2020;44:100672.
   PubMed Web of Science ®Google Scholar
• Zhao J, Niu X, Li X, et al. Inhibition of CHK1 enhances cell death induced by the bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells. Oncotarget. 2016;7(23):34785–34799.
   PubMedGoogle Scholar
• Han EK, Butler C, Zhang H, et al. Chkl binds and phosphorylates BAD protein. Anticancer Res. 2004;24(6):3907–3910.
   PubMed Web of Science ®Google Scholar
• Gatti-Mays ME, Karzai FH, Soltani SN, et al. A phase II single arm pilot study of the CHK1 inhibitor prexasertib (LY2606368) in BRCA wild-type, advanced triple-negative breast cancer. Oncologist. 2020;25(12):1013–e824.
   PubMedGoogle Scholar
• Iwasa S, Yamamoto N, Shitara K, et al. Dose-finding study of the checkpoint kinase 1 inhibitor, prexasertib, in Japanese patients with advanced solid tumors. Cancer Sci. 2018;109(10):3216–3223.
   PubMed Web of Science ®Google Scholar
• Wehler T, Thomas M, Schumann C, et al. A randomized, phase 2 evaluation of the CHK1 inhibitor, LY2603618, administered in combination with pemetrexed and cisplatin in patients with advanced nonsquamous non-small cell lung cancer. Lung Cancer. 2017;108:212–216.
   PubMed Web of Science ®Google Scholar
• Roberts AW, Seymour JF, Brown JR, et al. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol. 2012;30(5):488–496.
   PubMed Web of Science ®Google Scholar
• Roberts AW, Advani RH, Kahl BS, et al. Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the BCL2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory CD20+ lymphoid malignancies. Br J Haematol. 2015;170(5):669–678.
   PubMed Web of Science ®Google Scholar
• Wang L, Doherty GA, Judd AS, et al. Discovery of A-1331852, a first-in-class, potent, and orally-bioavailable BCL-X(L) inhibitor. ACS Med Chem Lett. 2020;11(10):1829–1836.
   PubMed Web of Science ®Google Scholar
• He Y, Koch R, Budamagunta V, et al. DT2216-a bcl-xL-specific degrader is highly active against bcl-xL-dependent T cell lymphomas. J Hematol Oncol. 2020;13(1):95.
   PubMed Web of Science ®Google Scholar